Drug delivery strategies for Alzheimer's disease treatment

Bibliography

• Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 2006;1:7-78
   Google Scholar
• Zhang HY. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 2005;579:5260-4
   PubMed Web of Science ®Google Scholar
• Richardson RL, Kim EM, Shepard RA, Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res 2002;954:1-10
   PubMed Web of Science ®Google Scholar
• Rohn TT, Rissman RA, Head E, Caspase activation in the Alzheimer's disease brain: tortuous and torturous. Drug News Perspect 2002;15:549-57
   PubMed Web of Science ®Google Scholar
• Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 2000;29:91-7
   PubMed Web of Science ®Google Scholar
• Stefanis L, Park DS, Friedman WJ, Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 1999;19:6235-47
   PubMed Web of Science ®Google Scholar
• Brauner DJ, Muir JC, Sachs GA. Treating non dementia illnesses in patients with dementia. JAMA 2000;283(24):3230-5
   PubMed Web of Science ®Google Scholar
• Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm 2004;19(4):352-62
   PubMedGoogle Scholar
• Mohamed S, Rosenheck R, Lyketsos K, Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry 2010;18(10):917-27
   Google Scholar
• Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004;11(5):456-67
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-97
   PubMed Web of Science ®Google Scholar
• Cutler DM, Everett W. Thinking outside the pillbox–medication adherence as a priority for health care reform. N Engl J Med 2010;362(17):1553-5
   PubMed Web of Science ®Google Scholar
• Arlt S, Lindner R, Rosier A, Adherence to medication in patients with dementia predictors and strategies for improvement. Drugs Aging 2008;25(12):1033-47
   PubMed Web of Science ®Google Scholar
• Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138(5):400-10
   PubMed Web of Science ®Google Scholar
• Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000;60(5):1095-122
   PubMed Web of Science ®Google Scholar
• Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of Tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab 2008;9(4):332-5
   PubMed Web of Science ®Google Scholar
• Bleich S, Romer K, Wiltfang J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18:S33-40
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG. The NMDA receptor antagonist Memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003;18(1):S23-32
   Google Scholar
• Information on Aricept®, Pfizer. Available from: www.aricept.com/ [Last accessed 10 December 2010]
   Google Scholar
• Black SE, Doody R, Li H, Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69(5):459-69
   PubMed Web of Science ®Google Scholar
• Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8(7):1011-23
   PubMed Web of Science ®Google Scholar
• Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001;18(11):853-62
   PubMed Web of Science ®Google Scholar
• Information on Exelon®, Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf [Last accessed 10 December 2010]
   Google Scholar
• Seltzer B. Galantamine-er for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging 2010;5:1-6
   PubMed Web of Science ®Google Scholar
• Information on Razadyne® ER, Ortho-McNeil Neurologics Inc. Available from: www.ortho-mcneilneurologics.com/products_razadyneer.html [Last accessed 07 April 2009]
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002;3:CD001747
   PubMedGoogle Scholar
• Galasko D, Kershaw PR, Schneider L, Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004;52(7):1070-6
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with Memantine). Int J Geriatr Psychiatry 1999;14:135-46
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving Donepezil. A randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimers disease. CNS Drugs 2009;23:293-307
   PubMed Web of Science ®Google Scholar
• Jones RW, Bayer A, Inglis F, Safety and tolerability of once-daily versus twice-daily Memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:258-62
   PubMed Web of Science ®Google Scholar
• Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry 2008;5(11):27-36
   PubMedGoogle Scholar
• Abetz L, Rofail D, Mertzanis P, Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009;26(6):627-44
   PubMed Web of Science ®Google Scholar
• Herrmann N, Binder C, Dalziel W, Persistence with cholinesterase inhibitor therapy for dementia an observational administrative health database study. Drugs Aging 2009;26(5):403-7
   PubMed Web of Science ®Google Scholar
• Muller MJ. Attitudes toward different formulations of psychotropic drugs: the view of patients and healthcare providers. Am J Drug Deliv 2006;4(1):33-41
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-309
   PubMed Web of Science ®Google Scholar
• Pushpangadan M, Feely M. Once a day is best: evidence or assumption? The relationship between compliance and dosage frequency in older people. Drugs Aging 1998;13(3):223-7
   PubMed Web of Science ®Google Scholar
• Muramatsu RS, Litzinger MHJ, Fisher E, Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother 2010;8:98-114
   PubMed Web of Science ®Google Scholar
• Comparison of 23 mg Donepezil sustained release (SR) to 10 mg Donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00478205 [Last accessed 25 April 2010]
   Google Scholar
• Farlow MR, Salloway S, Tariot PN, Effectiveness and tolerability of High-Dose (23 mg/d) versus Standard-dose (10 mg/d) Donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234-51
   PubMed Web of Science ®Google Scholar
• Open-Label Extension Study of 23 mg Donepezil SR in Patients with Moderate to Severe Alzheimer's disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00566501 [Last accessed 3 December 2009]
   Google Scholar
• Yan Y, Woo JS, Kang JH, Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Biol Pharm Bull 2010;33(8):1364-70
   PubMed Web of Science ®Google Scholar
• Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006;20:673-81
   PubMed Web of Science ®Google Scholar
• Zhao Q, Janssens L, Verhaeghe T, Pharmacokinetics of extended-release and immediate-release formulations of Galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005;21:1547-54
   PubMed Web of Science ®Google Scholar
• Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of Galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Curr Clin Pharmacol 2010;5:115-24
   PubMedGoogle Scholar
• Brodaty H, Corey-Bloom J, Potocnik FCV, Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120-32
   PubMed Web of Science ®Google Scholar
• Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily Galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther 2006;28:365-72
   PubMed Web of Science ®Google Scholar
• Scharre DW, Shiovitz T, Zhu Y, One-week dose titration of extended release Galantamine in patients with Alzheimer's disease. Alzheimers Dement 2008;4:30-7
   PubMed Web of Science ®Google Scholar
• Hing JP, Piotrovsky V, Kimko H, Pharmacokinetic simulation for switching from Galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005;21:483-8
   PubMed Web of Science ®Google Scholar
• Wolff A, Beiski BZ, Sela Y. Oral devices and methods for controlled drug delivery. WO2004069076; 2004
   Google Scholar
• Scholz OA, Wolff A, Schumacher A, Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 2008;13:247-53
   PubMed Web of Science ®Google Scholar
• Pather SI, Rathbone MJ, Senel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008;5(5):531-42
   PubMed Web of Science ®Google Scholar
• Giannola LI, Paderni C, De Caro V, New perspectives in delivery of Galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Curr Pharm Des 2010;16:653-9
   PubMed Web of Science ®Google Scholar
• Whelpton R, Hurst P. Bioavailability of oral Physostigmine. New Eng J Med 1985;313:1293-4
   PubMed Web of Science ®Google Scholar
• Bolourchian N, Hadidi N, Foroutan SM, Development and optimization of a sublingual tablet formulation for Physostigmine salicylate. Acta Pharm 2009;59:301-12
   PubMed Web of Science ®Google Scholar
• Information on Namenda XR®, Forest Pharmaceuticals. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/022525s000lbl.pdf [Last accessed June 2010]
   Google Scholar
• Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2010;11:1765-71
   PubMed Web of Science ®Google Scholar
• Utsuki T, Uchimura N, Irikura M, Preclinical investigation of the topical administration of Phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. J Pharmacol Exp Ther 2007;321(1):353-61
   PubMed Web of Science ®Google Scholar
• Subedi RK, Oh SY, Chun1 MK, Recent advances in transdermal drug delivery. Arch Pharm Res 2010;33(3):339-51
   PubMed Web of Science ®Google Scholar
• Chan ALF, Chien YW, Jin Lin S. Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects. Drugs Aging 2008;25:761-75
   PubMedGoogle Scholar
• Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23:357-75
   PubMed Web of Science ®Google Scholar
• Oertel W, Ross JS, Eggert K, Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69(4):S4-9
   Google Scholar
• Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol 2008;14:249-60
   PubMed Web of Science ®Google Scholar
• Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008;355:1-18
   PubMed Web of Science ®Google Scholar
• Motulsky A, Lafleur M, Couffin-Hoarau AC, Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants. Biomaterials 2005;26:6242-53
   PubMed Web of Science ®Google Scholar
• Packhaeuser CB, Schnieders J, Oster CG, In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445-55
   PubMed Web of Science ®Google Scholar
• Cummings J, Lefevre G, Small G, Pharmacokinetic rationale for the Rivastigmine patch. Neurology 2007;69(4):S10-13
   Google Scholar
• Emre M, Bernabei R, Blesa R, Drug profile: transdermal Rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010;16:246-53
   PubMed Web of Science ®Google Scholar
• Wentrup A, Oertel WH, Dodel R. Once-daily transdermal Rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther 2008;2:245-54
   Google Scholar
• Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal Rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009;63:799-805
   PubMed Web of Science ®Google Scholar
• Information on Exelon Patch®, Novartis Pharmaceuticals Corporation. Available from: http://www.exelonpatch.com/home.jsp [Last accessed 10 December 2010]
   Google Scholar
• Lefevre G, Pommier F, Sedek G, Pharmacokinetics and bioavailability of the novel Rivastigmine transdermal patch versus Rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008;48:246-52
   PubMed Web of Science ®Google Scholar
• Yang LPH, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. CNS Drugs 2007;21:957-65
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010;64:651-60
   PubMed Web of Science ®Google Scholar
• Sadowsky C, Davila Perez JA, Bouchard RW, Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010;16:51-60
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – Rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Grossberg G, Sadowsky C, Forstl H, Safety and tolerability of the Rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-64
   PubMed Web of Science ®Google Scholar
• Safety of switching from donepezil to rivastigmine patch in patients with probable Alzheimer's disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00428389 [Last accessed 17 December 2008]
   Google Scholar
• Sadowsky CH, Farlow MR, Meng X, Safety and tolerability of Rivastigmine transdermal patch compared with Rivastigmine capsules in patients switched from Donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-93
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral Rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 2010;9:167-76
   PubMed Web of Science ®Google Scholar
• Schmidt R, Alf C, Bancher C, Transdermal Rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatry 2009;23:58-63
   Google Scholar
• Mumoli N, Carmignani G, Luschi R, Hepatitis with cholestasis caused by Rivastigmine transdermal patch. Am J Gastroenterol 2009;104:2859-60
   PubMed Web of Science ®Google Scholar
• Effects of rivastigmine patch on activities of daily living and cognition in patients with severe dementia of the Alzheimer's type (ACTION). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00948766?term=Rivastigmine+Patch&rank=3 [Last accessed 30 March 2010]
   Google Scholar
• Comparative efficacy, safety, and tolerability of rivastigmine 10 and 15 cm2 patch in patients with Alzheimer's disease (AD) showing cognitive decline. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/NCT00506415 [Last accessed 7 August 2009]
   Google Scholar
• A 24 week open-label extension to study CENA713DUS44. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01054755 [Last accessed 1 February 2010]
   Google Scholar
• Vintiloiu A, Lafleur M, Bastiat G, In situ-forming oleogel implant for rivastigmine delivery. Pharm Res 2008;25(4):845-52
   PubMed Web of Science ®Google Scholar
• Bastiat G, Plourde F, Motulsky A, Tyrosine-based Rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials 2010;31:6031-8
   PubMed Web of Science ®Google Scholar
• Wei-Ze L, Mei-Rong H, Jian-Ping Z, Super-short solid silicon microneedles for transdermal drug delivery applications. Int J Pharm 2010;389:122-9
   PubMed Web of Science ®Google Scholar
• Benech H, Vincenti M, Fouchart F, Development and in vivo assessment of a transdermal system for Physostigmine. Methods Find Exp Clin Pharmacol 1998;20:489-98
   PubMed Web of Science ®Google Scholar
• Walter K, Muller M, Barkworth MF, Pharmacokinetics of Physostigmine in man following a single application of a transdermal system. Br J Clin Pharmac 1995;39:59-63
   PubMed Web of Science ®Google Scholar
• Moller HJ, Hampel H, Hegerl U, Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a Physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry 1999;32:99-106
   PubMed Web of Science ®Google Scholar
• Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001;2:CD001499
   Google Scholar
• Greig NH, Ruckle J, Comer P, Anticholinesterase and pharmacokinetic profile of Phenserine in healthy elderly human subjects. Curr Alzheimer Res 2005;2:483-92
   PubMedGoogle Scholar
• Greig NH, Sambamurti K, Yu Q-S, An overview of Phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005;2:281-90
   PubMedGoogle Scholar
• Telting-Diaz M, Lunte CE. Distribution of Tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm Res 1993;10:44-8
   PubMed Web of Science ®Google Scholar
• Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of Tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995;14:75-83
   Google Scholar
• Rawat S, Vengurlekar S, Rakesh B, Transdermal delivery by iontophoresis. Indian J Pharm Sci 2008;70:5-10
   PubMed Web of Science ®Google Scholar
• Jaskari T, Vuorio M, Kontturi K, Controlled transdermal iontophoresis by ion-exchange fiber. J Control Release 2000;67:179-90
   PubMed Web of Science ®Google Scholar
• Kankkunen T, Sulkava R, Vuorio M, Transdermal iontophoresis of Tacrine in vivo. Pharm Res 2002;19:704-7
   PubMed Web of Science ®Google Scholar
• Gore AV, Chien YW. The Nicotine transdermal system. Clin Dermatol 1998;16:599-615
   PubMed Web of Science ®Google Scholar
• Levin ED, Conners CK, Silva D, Transdermal Nicotine effects on attention. Psychopharmacology 1998;140:135-41
   PubMed Web of Science ®Google Scholar
• Min S, Moon IW, Ko R, Effects of transdermal Nicotine on attention and memory in healthy elderly non-smokers. Psychopharmacology 2002;159:83-8
   Web of Science ®Google Scholar
• White HK, Levin ED. Four-week Nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999;143:158-65
   PubMed Web of Science ®Google Scholar
• Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 2002;1:423-31
   PubMedGoogle Scholar
• Mulnard RA, Cotman CW, Kawas C, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007-15
   PubMed Web of Science ®Google Scholar
• Henderson VW, Paganini-Hill A, Miller BL, Estrogen for Alzheimer's disease in women. Neurology 2000;54:295-301
   PubMed Web of Science ®Google Scholar
• Asthana S, Craft S, Baker LD, Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999;24:657-77
   PubMed Web of Science ®Google Scholar
• Asthana S, Baker LD, Craft S, High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57:605-12
   PubMed Web of Science ®Google Scholar
• Wharton W, Gleason CE, Lorenze KR, Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. Am J Transl Res 2009;1:131-47
   PubMedGoogle Scholar
• Yue X, Lu M, Lancaster T, Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 2005;102:19198-203
   PubMed Web of Science ®Google Scholar
• Craig MC, Murphy DGM. Alzheimer's disease in women. Best Pract Res Clin Obstet Gynaecol 2009;23:53-61
   PubMed Web of Science ®Google Scholar
• Gleason CE, Carlsson CM, Johnson S, Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann NY Acad Sci 2005;1052:93-115
   PubMed Web of Science ®Google Scholar
• Chetkowski R, Meldrum D, Steingold K, Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615-20
   PubMed Web of Science ®Google Scholar
• Information on Estraderm Patch®, Novartis Pharmaceuticals Corporation. Available from: www.pharma.us.novartis.com/info/products/name/estraderm.jsp [Last accessed 25 February 2011]
   Google Scholar
• Baker LD, Sambamurti K, Craft S, 17beta-Estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study. Am J Geriatr Psychiatry 2003;11:239-44
   PubMed Web of Science ®Google Scholar
• Hall KA, Keks NA, O'Connor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr 2005;17:165-78
   PubMed Web of Science ®Google Scholar
• Frey WH II. Neurologic agents for nasal administration to the brain. WO1991007947; 1991
   Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Delivery of insuline-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-96
   PubMed Web of Science ®Google Scholar
• Sakane T, Akizuki M, Yoshida M, Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 1991;43:449-51
   PubMed Web of Science ®Google Scholar
• Sakane T, Akizuki M, Yamashita S, The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456-8
   PubMed Web of Science ®Google Scholar
• Kumar TA, David GFX, Sankaranarayanan A, Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc Natl Acad Sci USA 1982;79:4185-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Aun R, Tse FL. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 1998;19:571-5
   PubMed Web of Science ®Google Scholar
• Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 1999;88:754-8
   PubMed Web of Science ®Google Scholar
• Chow HH, Anavy N, Villalobos A. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci 2001;90:1729-35
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Throne RG, Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187:91-7
   PubMed Web of Science ®Google Scholar
• Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin 2004;25:522-7
   PubMed Web of Science ®Google Scholar
• Westin U, Piras E, Jansson B, Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005;24:565-73
   PubMed Web of Science ®Google Scholar
• Wang D, Gao Y, Yun L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 2006;57:97-104
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Schipper NG, Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38
   PubMed Web of Science ®Google Scholar
• Lee VH, Yamamoto A. Penetration and enzymatic barriers of peptide and protein absorption. Adv Drug Deliv Rev 1990;4:171-207
   Google Scholar
• Harris AS. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci 1986;75:1085-8
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm Res 2005;22:86-93
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
   PubMed Web of Science ®Google Scholar
• Costantino HR, Leonard AK, Brandt G, Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 2008;9(S6):1-3
   PubMedGoogle Scholar
• Paskov DS. Galanthamine. The handbook of experimental pharmacology. Volume 79. Springer Verlag, Berlin Heidleberg; 1986
   Google Scholar
• Leonard AK, Sileno AP, MacEvilly C, Development of a novel high-concentration Galantamine formulation suitable for intranasal delivery. J Pharm Sci 2005;94:1736-46
   PubMed Web of Science ®Google Scholar
• Leonard AK, Sileno AP, Brandt GC, In vitro formulation optimization of intranasal Galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 2007;335:138-46
   PubMed Web of Science ®Google Scholar
• Yamahita M, Yamashita M, Tanaka J, Vomiting induction by ipecac syrup in dogs and ferrets. J Toxicol Sci 1997;22:409-12
   PubMedGoogle Scholar
• Hasegawa M, Sasaki T, Sadakane K, Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets, involvement of 5-hydroxyptamine receptors. Jpn J Pharmacol 2002;89:113-19
   PubMedGoogle Scholar
• Snape MF, Misra A, Murray TK, A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors Tacrine, Donepezil and NXX-066. Neuropharmacology 1999;38:181-93
   PubMed Web of Science ®Google Scholar
• Dahlin M, Bjork E. Nasal administration of a Physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharm 2001;212:267-74
   PubMedGoogle Scholar
• Arumugam K, Subramanian GS, Mallayasamy SR, A study of Rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008;58:287-97
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, Nose-to-brain delivery of Tacrine. J Pharm Pharmacol 2007;59:1199-205
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, Intranasal mucoadhesive microemulsion of Tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 2008;22:116-24
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Traboulsi AA, Dittert LW, Targeted brain delivery of 17beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech 2002;3:40-7
   Google Scholar
• Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735-40
   PubMed Web of Science ®Google Scholar
• Nazem A, Mansoorib GA. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 2008;13:199-223
   PubMed Web of Science ®Google Scholar
• McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:585-94
   PubMed Web of Science ®Google Scholar
• Kogan MJ, Bastus NG, Amigo R, Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett 2006;6(1):110-15
   PubMed Web of Science ®Google Scholar
• Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006;7:65-74
   PubMed Web of Science ®Google Scholar
• Saini P, Greenspan P, Lu DR. Adsorption of brain proteins on the surface of Poly (D,L-lactide-co-glycolide) (PLGA) Microspheres. Drug Deliv 1997;4(2):129-34
   Web of Science ®Google Scholar
• Fournier E, Passirani C, Montero-Menei CN, Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003;24:3311-31
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen L, Gu W, In vitro and in vivo evaluation of Donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007;28:1882-8
   PubMed Web of Science ®Google Scholar
• Tan D, Zhao B, Moochhala S, Yang Y. Pharmacokinetic profile of a sustained-delivery system for Physostigmine in rats. Mater Sci Eng B 2006;132:155-8
   Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Poly(n-butylcyanoacrilate) nanoparticles coated with polysorbate 80 for the targeted delivery of Rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008;1200:159-68
   PubMed Web of Science ®Google Scholar
• Craparo EF, Pitarresi G, Bondi ML, A nanoparticulate drug-delivery system for Rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci 2008;8:247-59
   PubMed Web of Science ®Google Scholar
• Quizilbash N, Birks J, Lopez Arrieta J, Tacrine for Alzheimer's disease. Cochrane Database of Syst Rev 2000;3:CD000202
   Google Scholar
• Yang Q, Williams D, Owusu-Ababio G, Controlled release tacrine delivery systems for the treatment of Alzheimer's disease. Drug Deliv 2001;8:93-8
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Significant delivery of Tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. J Neurosci Methods 2009;177:427-33
   PubMed Web of Science ®Google Scholar
• Kumar V, Banker GS. Target-oriented drug delivery system. Marcel Dekker, New York; 1996
   Google Scholar
• Wilson B, Samanta MK, Santhi K, Targeted delivery of Tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008;70:75-84
   PubMed Web of Science ®Google Scholar
• Singh N, Seedat F, Pillay V, Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of Nicotine. J Microencapsul 2006;23(2):153-67
   PubMed Web of Science ®Google Scholar
• Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32(1):S2-9
   Google Scholar
• Christen Y. Oxidative stress and Alzheimer's disease. Am J Clin Nutr 2000;71:621S-9S
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Ehmann WD. Oxidative stress in Alzheimer's disease. Philadelphia: Lippincott Williams and Wilkins; 1999
   Google Scholar
• Kong S, Liochev S, Fridovich S. Aluminum (III) facilitates the oxidation of NADH by the superoxide anion. Free Radic Biol Med 1992;13(1):79-81
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Harris PLR, Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace imbalance. Neurosci Lett 2006;406:189-93
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Perry G, Smith M. Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease. J Nanoneurosci 2009;1(1):42-55
   PubMedGoogle Scholar
• Cui Z, Lockman PR, Atwood CS, Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS disease. Eur J Pharm Biopharm 2005;59:263-72
   PubMed Web of Science ®Google Scholar